Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1981 Jul;12(1):51–60. doi: 10.1111/j.1365-2125.1981.tb01854.x

Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis.

A Somogyi, M Albrecht, G Kliems, K Schäfer, M Eichelbaum
PMCID: PMC1401748  PMID: 7248141

Abstract

1 The pharmacokinetics, bioavailability and ECG response of verapamil was investigated in seven patients with liver cirrhosis and compared with six normal subjects, using stable labelled techniques whereby both the intravenous and oral dose are given simultaneously. 2 After intravenous administration, plasma concentrations were much higher in the patient group such that the total plasma clearance was reduced from a mean of 1258 ml/min in normals to 616 ml/min in the patient group (P less than 0.0025). The apparent volume of distribution nearly doubled (6.76 v 12.05 l/kg, P less than 0.025) and the terminal half-life was prolonged four fold (3.7 v 14.2 h, P less than 0.001). 3 Given orally, the peak plasma concentration was higher and occurred earlier in the liver cirrhotic patients. The absolute bioavailability more than doubled (22.0% normals v 52.3% liver cirrhotics, P less than 0.001) and apparent oral clearance was reduced to only 20% of normal (6.38 v 1.30 l/min, P less than 0.001). 4 The delta P-R interval in the patient group lagged behind the plasma concentration, in contrast to normal subjects. The maximum effect was much greater in the patients (15.4 v 41.6% increase, P less than 0.005) and persisted for a longer period of time. The slope of the plasma concentration-response curve was the same as in normals after intravenous administration. Plasma protein binding remained unchanged. 5 It is recommended that in liver cirrhotic patients the intravenous dose of verapamil be halved and the oral dose decreased by a factor of five in order to prevent untoward effects. As well as a steady-state plasma concentration will not be reached until approximately 2 days after the beginning of therapy.

Full text

PDF
51

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Blaschke T. F., Rubin P. C. Hepatic first-pass metabolism in liver disease. Clin Pharmacokinet. 1979 Nov-Dec;4(6):423–432. doi: 10.2165/00003088-197904060-00002. [DOI] [PubMed] [Google Scholar]
  2. Boxenbaum H. G., Riegelman S., Elashoff R. M. Statistical estimations in pharmacokinetics. J Pharmacokinet Biopharm. 1974 Apr;2(2):123–148. doi: 10.1007/BF01061504. [DOI] [PubMed] [Google Scholar]
  3. Eichelbaum M., Albrecht M., Kliems G., Schäfer K., Somogyi A. Influence of meso-caval shunt surgery on verapamil kinetics, bioavailability and response. Br J Clin Pharmacol. 1980 Nov;10(5):527–530. doi: 10.1111/j.1365-2125.1980.tb01800.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Eichelbaum M., Birkel P., Grube E., Gütgemann U., Somogyi A. Effects of verapamil on P-R-intervals in relation to verapamil plasma levels following single I.V. and oral administration and during chronic treatment. Klin Wochenschr. 1980 Sep 15;58(18):919–925. doi: 10.1007/BF01477049. [DOI] [PubMed] [Google Scholar]
  5. Eichelbaum M., Ende M., Remberg G., Schomerus M., Dengler H. J. The metabolism of DL-[14C]verapamil in man. Drug Metab Dispos. 1979 May-Jun;7(3):145–148. [PubMed] [Google Scholar]
  6. Eichelbaum M., Somogyi A., von Unruh G. E., Dengler H. J. Simultaneous determination of the intravenous and oral pharmacokinetic parameters of D,L-verapamil using stable isotope-labelled verapamil. Eur J Clin Pharmacol. 1981 Jan;19(2):133–137. doi: 10.1007/BF00568400. [DOI] [PubMed] [Google Scholar]
  7. Galeazzi R. L., Benet L. Z., Sheiner L. B. Relationship between the pharmacokinetics and pharmacodynamics of procainamide. Clin Pharmacol Ther. 1976 Sep;20(3):278–289. doi: 10.1002/cpt1976203278. [DOI] [PubMed] [Google Scholar]
  8. Gibaldi M., McNamara P. J. Tissue binding of drugs. J Pharm Sci. 1977 Aug;66(8):1211–1212. doi: 10.1002/jps.2600660846. [DOI] [PubMed] [Google Scholar]
  9. Neal E. A., Meffin P. J., Gregory P. B., Blaschke T. F. Enhanced bioavailability and decreased clearance of analgesics in patients with cirrhosis. Gastroenterology. 1979 Jul;77(1):96–102. [PubMed] [Google Scholar]
  10. Paumgartner G. The handling of indocyanine green by the liver. Schweiz Med Wochenschr. 1975;105(17 Suppl):1–30. [PubMed] [Google Scholar]
  11. Schober O., Mariss P., Schmidt F. W., Hundeshagen H. Total body water, extracellular water, plasma volume, and total body potassium in cirrhosis of the liver. Klin Wochenschr. 1979 Aug 1;57(15):757–761. doi: 10.1007/BF01478033. [DOI] [PubMed] [Google Scholar]
  12. Schomerus M., Spiegelhalder B., Stieren B., Eichelbaum M. Physiological disposition of verapamil in man. Cardiovasc Res. 1976 Sep;10(5):605–612. doi: 10.1093/cvr/10.5.605. [DOI] [PubMed] [Google Scholar]
  13. Serlin M. J., Sibeon R. G., Mossman S., Breckenridge A. M., Williams J. R., Atwood J. L., Willoughby J. M. Cimetidine: interaction with oral anticoagulants in man. Lancet. 1979 Aug 18;2(8138):317–319. doi: 10.1016/s0140-6736(79)90340-4. [DOI] [PubMed] [Google Scholar]
  14. Shanks C. A., Somogyi A. A., Triggs E. J. Dose-response and plasma concentration-response relationships of pancuronium in man. Anesthesiology. 1979 Aug;51(2):111–118. doi: 10.1097/00000542-197908000-00004. [DOI] [PubMed] [Google Scholar]
  15. Sheiner L. B., Stanski D. R., Vozeh S., Miller R. D., Ham J. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther. 1979 Mar;25(3):358–371. doi: 10.1002/cpt1979253358. [DOI] [PubMed] [Google Scholar]
  16. Spiegelhalder B., Eichelbaum M. Determination of verapamil in human plasma by mass fragmentography using stable isotope-labelled verapamil as internal standard. Arzneimittelforschung. 1977;27(1):94–97. [PubMed] [Google Scholar]
  17. Vestal R. E., Wood A. J., Branch R. A., Shand D. G., Wilkinson G. R. Effects of age and cigarette smoking on propranolol disposition. Clin Pharmacol Ther. 1979 Jul;26(1):8–15. doi: 10.1002/cpt19792618. [DOI] [PubMed] [Google Scholar]
  18. Wagner J. G. Linear pharmacokinetic equations allowing direct calculation of many needed pharmacokinetic parameters from the coefficients and exponents of polyexponential equations which have been fitted to the data. J Pharmacokinet Biopharm. 1976 Oct;4(5):443–467. doi: 10.1007/BF01062831. [DOI] [PubMed] [Google Scholar]
  19. Wood A. J., Kornhauser D. M., Wilkinson G. R., Shand D. G., Branch R. A. The influence of cirrhosis on steady-state blood concentrations of unbound propranolol after oral administration. Clin Pharmacokinet. 1978 Nov-Dec;3(6):478–487. doi: 10.2165/00003088-197803060-00005. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES